Diving into New and Emerging Non-Factor Therapies for Hemophilia and Discussing Advancements in New Options and Monitoring with Patients

Faculty

Maya Bloomberg, APRN, FNP-BC
Hematology Nurse Practitioner
University of Miami Hemophilia Treatment Center
Sylvester Comprehensive Cancer Center
Jackson Memorial Hospital
Miami, FL
Guy Young, MD
Moderator
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disease Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, CA

Statement of Need

Recent advances in the treatment of hemophilia, a genetically X-linked bleeding disorder, include non-factor prophylactic therapies such as factor VIII mimetics, anti-tissue factor pathway inhibitors (anti-TFPIs) and small interfering RNA (siRNA) treatments. Health care professionals (HCPs) treating patients with hemophilia utilizing the current, less-than-optimal factor replacement therapies experience limitations such as problems with bleed control, inhibitor development, joint damage, and patient adherence issues and would benefit from learning about the latest clinical data on non-factor treatment approaches for hemophilia from the scientific literature of the past 12 months.

This CMEO Journal Club will equip HCPs with the latest evidence from recent clinical trials and scientific literature, enabling them to evaluate new prophylactic strategies and incorporate non-factor therapies into comprehensive, individualized treatment plans. Expert faculty will translate data into real-world insights to support improved patient outcomes and long-term disease management.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Integrate the latest clinical trial updates when developing optimal prophylactic treatment approaches with non-factor therapy to prevent bleeding episodes and minimize risk of long-term complications for patients with hemophilia

Financial Support

Supported by an educational grant from Novo Nordisk Inc.

Target Audience

Hematologists, hemophilia treatment center allied HCPs including nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-25-073-H01-P).

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.75 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 08/08/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Ms. Bloomberg reports the following financial relationships:

Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; and Sanofi

Speakers Bureau: Bayer; Genentech, Inc.; Novo Nordisk; and Sanofi

Dr. Young reports the following financial relationships:

Advisory Board: Alnylam Pharmaceuticals, Inc.; Bayer Corporation; CSL Behring; Genentech, Inc./Roche; HEMA Biologics, LLC; Novo Nordisk; Octapharma Plasma; Pfizer Inc.; Sanofi; and Takeda Pharmaceutical Company Limited

Consultant: Alnylam Pharmaceuticals, Inc.; ASC Biosciences, Inc.; Bayer Corporation; BioMarin; CSL Behring; Genentech, Inc./Roche; HEMA Biologics, LLC/LFB; Novo Nordisk; Octapharma Plasma; Pfizer Inc.; Sanofi Genzyme; Spark Therapeutics, Inc.; and Takeda Pharmaceutical Company Limited

Grants: Sanofi

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Felicia Oyedepo, MD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

JC-035-080825-68

Diving into New and Emerging Non-Factor Therapies for Hemophilia and Discussing Advancements in New Options and Monitoring with Patients
Event Date: 08/08/2025